259 related articles for article (PubMed ID: 26697891)
1. Development of a level A in vitro-in vivo correlation for extended release dosage forms of quetiapine fumarate.
Gonçalves de Lima L; Rossi de Campos D
Drug Res (Stuttg); 2016 May; 66(5):225-9. PubMed ID: 26697891
[TBL] [Abstract][Full Text] [Related]
2. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers.
Estevez-Carrizo FE; Parrillo S; Ercoli MC; Estevez-Parrillo FT
Clin Ther; 2011 Jun; 33(6):738-45. PubMed ID: 21704238
[TBL] [Abstract][Full Text] [Related]
3. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
4. Solid Lipid Nanoparticles Approach for Lymphatic Targeting Through Intraduodenal Delivery of Quetiapine Fumarate.
Yasir M; Gaur PK; Puri D; Shehkar P; Kumar SS
Curr Drug Deliv; 2018; 15(6):818-828. PubMed ID: 28545354
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics Analysis of Quetiapine Extended-release Formulation in Japanese Patients with Bipolar Depression.
Fukushi R; Nomura Y; Katashima M; Komatsu K; Sato Y; Takada A
Clin Ther; 2020 Jun; 42(6):1067-1076.e2. PubMed ID: 32518042
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.
Figueroa C; Brecher M; Hamer-Maansson JE; Winter H
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):199-204. PubMed ID: 18948162
[TBL] [Abstract][Full Text] [Related]
7. Steady-state bioequivalence 2-way crossover study of two quetiapine prolonged-release 400 mg tablet formulations in normal male and female healthy subjects under fasting conditions
.
Trabelsi F; Gharavi N; Kalovidouris M; Nikolaidou M
Int J Clin Pharmacol Ther; 2016 Sep; 54(9):732-42. PubMed ID: 27443660
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic evaluation of quetiapine fumarate controlled release hybrid hydrogel: a healthier treatment of schizophrenia.
Akhlaq M; Maryam F; Elaissari A; Ullah H; Adeel M; Hussain A; Ramzan M; Ullah O; Zeeshan Danish M; Iftikhar S; Aziz N
Drug Deliv; 2018 Nov; 25(1):916-927. PubMed ID: 29649903
[TBL] [Abstract][Full Text] [Related]
9. Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.
Mittapalli RK; Nuthalapati S; Delke DeBord AE; Xiong H
Pharm Res; 2017 Jun; 34(6):1187-1192. PubMed ID: 28243955
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
11. Extended release dosage form of glipizide: development and validation of a level A in vitro-in vivo correlation.
Ghosh A; Bhaumik UK; Bose A; Mandal U; Gowda V; Chatterjee B; Chakrabarty US; Pal TK
Biol Pharm Bull; 2008 Oct; 31(10):1946-51. PubMed ID: 18827360
[TBL] [Abstract][Full Text] [Related]
12. In-vitro and in-vivo correlation for two gliclazide extended-release tablets.
Mandal U; Ray KK; Gowda V; Ghosh A; Pal TK
J Pharm Pharmacol; 2007 Jul; 59(7):971-6. PubMed ID: 17637192
[TBL] [Abstract][Full Text] [Related]
13. An understanding of modified release matrix tablets behavior during drug dissolution as the key for prediction of pharmaceutical product performance - case study of multimodal characterization of quetiapine fumarate tablets.
Kulinowski P; Woyna-Orlewicz K; Rappen GM; Haznar-Garbacz D; Węglarz WP; Dorożyński PP
Int J Pharm; 2015 Apr; 484(1-2):235-45. PubMed ID: 25701626
[TBL] [Abstract][Full Text] [Related]
14. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications.
Bui K; Earley W; Nyberg S
Curr Med Res Opin; 2013 Jul; 29(7):813-25. PubMed ID: 23574265
[TBL] [Abstract][Full Text] [Related]
16. Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.
Zhang Y; Liu H; Tang MJ; Ho NJ; Shek TL; Yang Z; Zuo Z
AAPS J; 2021 Mar; 23(2):38. PubMed ID: 33665728
[TBL] [Abstract][Full Text] [Related]
17. Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents.
Johnson TN; Zhou D; Bui KH
Biopharm Drug Dispos; 2014 Sep; 35(6):341-52. PubMed ID: 24797229
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression.
Rajagopalan K; Meyer K; O'Day K; Denno M; Loebel A
J Med Econ; 2015; 18(10):821-7. PubMed ID: 25985265
[TBL] [Abstract][Full Text] [Related]
19. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J
Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663
[TBL] [Abstract][Full Text] [Related]
20. Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation.
Mohamed MF; Trueman S; Othman AA; Han JH; Ju TR; Marroum P
AAPS J; 2019 Oct; 21(6):108. PubMed ID: 31654328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
